Managing Electroconvulsive Therapy

Managing Electroconvulsive Therapy

Documents ECT treatment parameters, seizure quality assessment, cognitive monitoring protocols, and informed consent in compliance with APA Task Force on ECT guidelines and institutional requirements.

Why This Skill Exists

Electroconvulsive therapy (ECT) remains the most effective treatment for severe, treatment-resistant depression, with response rates of 50-70% in patients who have failed multiple medication trials. It is also first-line treatment for catatonia, life-threatening psychiatric emergencies (severe suicidality, psychotic depression with refusal to eat/drink, malignant neuroleptic syndrome), and treatment-resistant mania and schizophrenia. Despite its efficacy, ECT is one of the most heavily regulated and documented psychiatric treatments due to its history of controversy and the requirement for general anesthesia.

The APA Task Force on Electroconvulsive Therapy (Practice of ECT: Recommendations for Treatment, Training, and Privileging) establishes standards for patient selection, informed consent, treatment parameters, seizure adequacy, cognitive monitoring, and continuation/maintenance protocols. CMS Conditions of Participation require informed consent documentation, pre-treatment medical evaluation, anesthesia clearance, and treatment documentation for each session. Inadequate documentation of ECT treatment parameters, seizure quality, or cognitive monitoring is a frequent finding in Joint Commission surveys and a basis for malpractice claims when cognitive side effects occur.

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the clinical indication for ECT? (treatment-resistant depression, catatonia, acute suicidality, psychotic depression, treatment-resistant mania, treatment-resistant schizophrenia, neuroleptic malignant syndrome, status epilepticus) — default: specify indication
2. Is this an index course, continuation, or maintenance ECT? — default: index course
3. Has informed consent been obtained? (patient consent, surrogate consent, court-ordered) — default: obtain before first treatment
4. What is the patient's cardiac and anesthesia risk? (ASA classification) — default: obtain anesthesia evaluation
5. What medications is the patient currently taking? (benzodiazepines, anticonvulsants, and lithium affect seizure threshold and must be managed) — default: review and adjust
6. Has baseline cognitive testing been completed? (MoCA or MMSE required before index course) — default: administer before first treatment
7. What electrode placement will be used? (right unilateral, bilateral bitemporal, bifrontal) — default: right unilateral at suprathreshold dosing
8. Is the patient on an inpatient unit or receiving outpatient ECT? — default: identify setting and transport plan

Documents to Request

• Pre-ECT psychiatric evaluation documenting indication and treatment resistance
• Documentation of failed medication trials (agents, doses, durations, reasons for failure)
• Medical evaluation: physical exam, cardiac history, pulmonary history
• Pre-ECT laboratory results: CBC, CMP, ECG, chest X-ray (if indicated)
• Anesthesia pre-evaluation and clearance
• Brain imaging (MRI or CT) — required if space-occupying lesion is a concern
• Baseline cognitive assessment (MoCA or MMSE)
• Informed consent documentation
• Previous ECT treatment records (if repeat course)
• Current medication list with adjustments for ECT

Step 1: Pre-Treatment Evaluation and Consent

Medical Evaluation

• Cardiac evaluation: ECG, cardiac history (arrhythmias, recent MI, pacemaker/ICD)
• Pulmonary evaluation: History of COPD, asthma, obstructive sleep apnea (affects ventilation)
• Neurological evaluation: History of seizure disorder, intracranial mass, recent stroke, elevated ICP (absolute contraindication: pheochromocytoma; relative: raised ICP, recent cerebral hemorrhage)
• Dental evaluation: Loose teeth, dentures (aspiration risk during seizure)
• Medication adjustment:
  • Taper and hold benzodiazepines (raise seizure threshold, reduce efficacy)
  • Hold anticonvulsants if possible (raise seizure threshold)
  • Reduce or hold lithium (increased risk of post-ictal delirium, neurotoxicity)
  • Continue antidepressants and antipsychotics (generally safe, may enhance efficacy)
  • Hold theophylline (prolongs seizure, increases status epilepticus risk)

Informed Consent

Document informed consent discussion covering:

• Nature of ECT procedure (anesthesia, muscle relaxant, electrical stimulation, induced seizure)
• Expected benefits and response timeline (typically improvement within 6-12 treatments)
• Common side effects: headache (45%), muscle soreness (25%), nausea (25%), transient confusion
• Cognitive side effects: anterograde amnesia (difficulty forming new memories during treatment course), retrograde amnesia (loss of memories from period around treatment — usually temporary, but some autobiographical memory loss may persist)
• Risks: anesthesia risks, rare cardiac events, prolonged seizure, aspiration
• Alternative treatments available
• Right to withdraw consent at any time
• Number and frequency of treatments planned (typically 6-12, three times per week)

If the patient lacks capacity to consent, document the basis for surrogate consent or court authorization.

Step 2: Treatment Parameters and Documentation

Per-Treatment Documentation Requirements

Pre-treatment:

• Vital signs (BP, HR, O2 saturation, temperature)
• NPO status confirmed (nothing by mouth for ≥8 hours for solids, ≥2 hours for clear liquids)
• Current medications taken/held
• Brief mental status assessment
• Informed consent confirmed as still valid

Treatment parameters to document:

• Electrode placement: Right unilateral (RUL), bilateral bitemporal (BT), or bifrontal (BF)
  • RUL: Fewer cognitive side effects, requires higher dose relative to seizure threshold (typically 6x threshold)
  • BT: More effective for some patients, greater cognitive side effects, dose at 1.5-2.5x threshold
  • BF: Intermediate profile, less studied
• Stimulus parameters: Charge (millicoulombs), frequency (Hz), pulse width (ms), stimulus duration (seconds), current (mA)
• Seizure threshold titration: Typically performed at first treatment — start at low dose, increase incrementally until seizure is achieved
• Anesthetic agents: Methohexital (preferred — least seizure threshold elevation) or propofol (more commonly available). Document dose.
• Muscle relaxant: Succinylcholine (typical) or rocuronium (if succinylcholine contraindicated). Document dose.
• Anticholinergic: Glycopyrrolate (to reduce secretions and vagal bradycardia). Document if given.

Seizure monitoring and quality:

• EEG seizure duration: Motor (cuff method) and EEG duration. Adequate seizure: ≥15-20 seconds motor, ≥25 seconds EEG.
• Seizure quality indicators on EEG: High-amplitude polyspike activity, post-ictal suppression (associated with efficacy)
• Missed seizure: If no seizure, restimulate at higher dose (maximum 2-3 restimulations per session)
• Prolonged seizure: >120 seconds — treat with additional propofol or midazolam; document intervention

Post-treatment:

• Vital signs in recovery (BP, HR, O2 sat) every 5 minutes until stable
• Time to reorientation (key cognitive metric — track across treatments)
• Post-ictal confusion duration and severity
• Post-treatment headache, nausea, or other complaints
• Mental status before discharge from recovery area

Step 3: Cognitive Monitoring Protocol

Cognitive monitoring is required at baseline, during the treatment course, and after completion:

Baseline (before first treatment):

• MoCA or MMSE (document score)
• Orientation assessment (time, place, person, situation)
• Autobiographical Memory Interview (AMI) or equivalent — establish baseline for personal memory
• Record current cognitive complaints

During treatment course (every 3-4 treatments):

• Repeat MoCA or MMSE
• Time to reorientation after each treatment (trend across sessions)
• Patient self-report of memory difficulties
• Clinical assessment of anterograde and retrograde memory function
• If significant cognitive decline (>4-point drop on MoCA or extended reorientation time), consider:
  • Switching from bilateral to right unilateral placement
  • Reducing treatment frequency (from 3x/week to 2x/week)
  • Increasing inter-treatment interval
  • Reducing stimulus dose
  • Switching anesthetic agent

Post-course (1-2 weeks after final treatment and at 1, 3, 6 months):

• MoCA or MMSE
• Subjective cognitive complaints assessment
• Functional cognitive assessment (return to work, managing medications, driving)
• If persistent cognitive complaints at 3-6 months, refer for neuropsychological testing

Step 4: Treatment Course Management

Response monitoring:

• Administer PHQ-9 or MADRS (Montgomery-Asberg Depression Rating Scale) before each treatment or weekly
• Document clinical impression of improvement (CGI-S and CGI-I)
• Typical response: significant improvement by treatments 6-8
• Full course: typically 6-12 treatments (continue until plateau — two consecutive treatments without further improvement)

If inadequate response after 6 treatments:

• Switch electrode placement (RUL to BT if on RUL)
• Increase stimulus dose
• Ensure adequate seizure quality
• Review concurrent medications for seizure threshold interference
• Re-evaluate diagnosis

Continuation/Maintenance ECT:

• After successful index course, taper frequency: weekly x 4, then biweekly x 4, then monthly
• Continue maintenance ECT if patient has history of relapse after stopping, or if medication intolerance prevents adequate pharmacotherapy
• Document indication for continuation/maintenance at each session
• Continue cognitive monitoring at each maintenance session

Step 5: Discharge Planning and Post-ECT Care

• Document total number of treatments, electrode placement used, and cumulative clinical response
• Transition to maintenance pharmacotherapy (lithium augmentation of antidepressant is the most evidence-based relapse prevention strategy post-ECT)
• Schedule follow-up cognitive assessment at 1, 3, and 6 months post-course
• Counsel patient on expected cognitive recovery timeline (most anterograde memory normalizes within 2-4 weeks; some retrograde gaps may persist)
• Provide written post-ECT instructions including driving restrictions (typically no driving for 24 hours after each treatment, longer if cognitive effects persist)
• Discuss maintenance ECT option if applicable

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the clinical indication for ECT documented with evidence of treatment resistance?
2. Is informed consent documented with cognitive side effect discussion?
3. Are treatment parameters documented for each session (electrode placement, stimulus dose, seizure duration)?
4. Is cognitive monitoring documented at baseline and during the course with specific scores?
5. Is the post-ECT transition plan documented (maintenance ECT vs. pharmacotherapy)?

Quality Audit

• Indication for ECT documented with DSM-5-TR diagnosis and treatment resistance documentation
• Informed consent obtained and documented with cognitive risk discussion
• Pre-ECT medical evaluation and anesthesia clearance documented
• Baseline cognitive assessment (MoCA or MMSE) score documented
• Medication adjustments documented (benzodiazepine taper, anticonvulsant hold)
• Per-treatment documentation includes: electrode placement, stimulus parameters, seizure duration (motor and EEG), anesthetic and muscle relaxant doses
• Seizure quality assessed at each treatment (adequate duration, EEG morphology)
• Time to reorientation tracked across treatments
• Response monitored with validated scale (PHQ-9 or MADRS) at regular intervals
• Cognitive monitoring performed every 3-4 treatments with documented scores
• Protocol for managing cognitive decline or inadequate seizure documented
• Total course documented (number of treatments, electrode placement, cumulative response)
• Post-ECT follow-up plan including cognitive reassessment at 1, 3, 6 months
• Continuation/maintenance ECT plan or pharmacotherapy transition documented

Guidelines

1. Never administer ECT without documented informed consent that specifically addresses cognitive side effects — cognitive risks are the most common patient concern and the most common basis for ECT-related litigation.
2. Always obtain baseline cognitive testing before the first treatment — without baseline data, it is impossible to determine whether post-ECT cognitive complaints represent a change from pre-treatment functioning.
3. Hold benzodiazepines and anticonvulsants when clinically safe — these agents raise the seizure threshold and reduce ECT efficacy. Document the clinical reasoning if they must be continued.
4. Track time to reorientation across treatments — progressive prolongation of reorientation time is the most sensitive early indicator of excessive cognitive burden and should prompt parameter adjustment.
5. Right unilateral electrode placement at 6x seizure threshold is the recommended starting approach — it provides equivalent efficacy to bilateral with significantly fewer cognitive effects per the Columbia University/CORE ECT consortium data.
6. If no seizure is achieved, do not exceed 3 restimulation attempts per session — excessive stimulation without seizure increases cognitive risk without therapeutic benefit.
7. For catatonia, ECT should be initiated promptly if benzodiazepine challenge (lorazepam 1-2mg IV) does not produce response within 48-72 hours — delayed ECT for catatonia increases morbidity and mortality.